Skip to content
Clinical Trials – home
DenmarkBack to Denmark

Clinical trials in Koege – page 70

1 198 clinical trials in Koege, Denmark across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

DenmarkOur site in DenmarkKliniske-Forsoeg.dk(opens in a new tab)
Koege at a glance
1 198
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 198 trials in Koege

Open in trial search

Glioma

Not recruiting

Study of Abemaciclib and Temozolomide for Children and Young Adults with Newly Diagnosed High-Grade Glioma After Radiotherapy

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.

Study on the Effectiveness and Safety of Losmapimod for Patients with Facioscapulohumeral Muscular Dystrophy (FSHD)

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Losmapimod
  • Sponsor:Fulcrum Therapeutics Inc.

Myotonic dystrophy

Not recruiting

Study on AOC 1001 for Treating Myotonic Dystrophy Type 1 in Patients

Investigational
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:AOC 1001
  • Sponsor:Avidity Biosciences Inc.

Long-term Safety Study of Onasemnogene Abeparvovec for Patients with Spinal Muscular Atrophy

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Onasemnogene Abeparvovec
  • Sponsor:Novartis Pharma AG

Study on the Effectiveness and Safety of Mitapivat for Children with Pyruvate Kinase Deficiency Receiving Regular Blood Transfusions

Investigational
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:Mitapivat
  • Sponsor:Agios Pharmaceuticals Inc.

Study of eftilagimod alpha with pembrolizumab combination therapy for patients with metastatic head and neck cancer who have not received previous treatment

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Eftilagimod Alfa
  • Sponsor:Immutep

Study on CLIC-1901 CAR T-cells and Tocilizumab for Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Clic-1901 Cart
  • Sponsor:Region Hovedstaden

Study on the Effects and Safety of Efgartigimod PH20 SC for Adults with Active Idiopathic Inflammatory Myopathy

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

K-ras gene mutation+2

Not recruiting

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study of remibrutinib for long-term treatment of adult patients with chronic spontaneous urticaria who completed previous remibrutinib studies

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Fenebrutinib and Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Myocardial infarction

Not recruiting

Study on the Effects of Carvedilol, Metoprolol Tartrate, and Bisoprolol Fumarate in Patients After a Heart Attack with Normal Heart Pumping Function

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Bisoprolol Fumarate
  • Sponsor:Frederiksberg Hospital

Other cities in Denmark

The busiest research cities in the country

All 45 cities in Denmark

Clinical research in Koege

What the registry says about research in the country

01 Cardiovascular and Emergency Care Research

Clinical trials in Køge are exploring cardiovascular diseases and acute care, with a focus on improving outcomes for patients with hypotension and shock. These studies are designed to test new treatment approaches that may help stabilize patients faster and reduce the need for intensive care.

  • Early treatment strategies for low blood pressure and shock
  • New approaches to reduce cardiovascular risk
  • Supportive care for emergency department patients

The research reflects a strong interest in faster, more effective care for serious circulatory conditions.

02 Diabetes and Metabolic Disease Studies

Several trials are centered on type 1 diabetes and related nutritional and metabolic diseases, including efforts to lower long-term cardiovascular complications. The research is aimed at testing whether more intensive care strategies and new treatment options can improve health outcomes for people living with diabetes.

  • Intensified care for people with type 1 diabetes at high cardiovascular risk
  • Evaluating protective treatment options for heart-related complications
  • Improving long-term disease control in diabetes

These studies combine prevention and treatment research to support better chronic disease management.

03 Bone, Joint, and Musculoskeletal Research

Research in musculoskeletal diseases includes trials for diabetic acute Charcot foot, a serious complication that can affect mobility and bone health. The main purpose is to evaluate whether a new treatment approach can improve healing and protect patients from further damage.

  • Treatment options for acute Charcot foot in diabetes
  • Restoring function and reducing complications
  • Clinical outcomes in diabetic foot care

This area of research is especially important for preserving movement and quality of life.

04 Ear, Nose, and Throat Research

Trials in otorhinolaryngologic diseases are focusing on chronic rhinosinusitis with nasal polyps, also known as CRSwNP. These studies are assessing whether patients who have responded well to biologic treatment can safely reduce or stop therapy without symptoms returning.

  • Long-term management of nasal polyps
  • Testing the durability of biologic treatment responses
  • Reducing treatment burden while maintaining disease control

This research aims to make care more tailored for people with persistent sinus disease.

05 Digestive System and Gastrointestinal Research

Clinical trials in digestive system diseases are investigating bile acid diarrhoea, with the goal of improving stool consistency and overall symptom control. The studies are evaluating whether a new tablet formulation can provide meaningful relief compared with placebo.

  • Symptom control in bile acid diarrhoea
  • Testing a new treatment for better bowel function
  • Improving quality of life for patients with chronic diarrhoea

These trials focus on practical treatment benefits that matter in everyday care.

06 Hormonal and Chronic Disease Care

Trials linked to hormonal diseases are also part of the research landscape, especially through studies involving diabetes-related complications and broader chronic disease management. The aim is to better understand how targeted therapies can support patients with complex, long-term conditions.

  • Chronic disease control in people with endocrine-related conditions
  • Supporting safer treatment strategies
  • Exploring therapies that may improve long-term outcomes

In Køge, this area connects closely with ongoing diabetes research and prevention-focused care.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.